Stock WVE WAVE LIFE SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
5.21 USD -0.76% Intraday chart for Wave Life Sciences Ltd. -13.02% +3.17%
06-24 Wave Life Sciences Ltd.(NasdaqGM:WVE) added to S&P Pharmaceuticals Select Industry Index CI
05-15 Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Presentation: Unlocking the Edit Verse: Combining Machine Learning & Multiple AIMer Applications to Build a High Impact RNA Editing Pipeline
PU
Presentation: RestorAATion: The First Clinical Program Evaluating an RNA Editing Therapeutic in Humans
PU
Wave Life Sciences : Speaker Presentation
PU
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
GL
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
GL
Wave Life Sciences : Improving the Potency and Sequence Versatility of RNA Editing Through Oligonucleotide Chemical Modifications
PU
Wave Life Sciences : Impact of Phosphoryl Guanidine (PN) Variants on siRNA Potency and Durability in Hepatic and Extrahepatic Tissues
PU
First clinical evidence for myocyte stem (satellite) cell targeting in DMD: Results from Part A of a Phase 1b/2 study of WVE-N531
PU
A Phase 1b/2 Open label Study of WVE N531 in Patients with Duchenne Muscular Dystrophy: Part B (FORWARD 53) Study Design and Rationale
PU
Wave Life Sciences : Interview with Wave Speakers
PU
Wave Life Sciences : Potent, Durable mRNA Knockdown in Extrahepatic Tissues Using siRNAs With Novel Phosphoryl Guanidine Backbone Variants
PU
Wave Life Sciences : Chemical Design of Oligonucleotides That Support Targeted RNA Editing in the CNS of Non-Human Primates
PU
Wave Life Sciences: Q1 Earnings Snapshot
AQ
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
GL
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
GL
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
GL
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
GL
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GL
Wave Life Sciences to Present at Upcoming Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WVE Stock
  4. News Wave Life Sciences Ltd.
  5. Press Releases